Fermenta Biotech Ltd
Fermenta Biotech Q1 FY25 earnings call: Revenue & Margins
Q1 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹78Cr
- Net profit
- −₹6Cr
- Margin
- 1.02%
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Fermenta Biotech Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1-FY25 consolidated operational revenue: INR 781 million, down 5.3% YoY (Q1-FY24: INR 824 million). Q1-FY25 Consolidated Financials: - EBITDA: INR 8 Mn (down 92.7% YoY from INR 109 Mn in Q1-FY24) - EBITDA Margin: 1.02% (down from 13.26% YoY) - Profit After Tax (PAT): INR (59) Mn (loss, compa
From Fermenta Biotech Ltd's Q1 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1-FY25 consolidated operational revenue: INR 781 million, down 5.3% YoY (Q1-FY24: INR 824 million).
- Q1-FY25 standalone operational revenue: INR 727 million, down 5.3% YoY (Q1-FY24: INR 768 million).
- Vitamin D3 for Human Nutrition volumes in Q1-FY25 rose by 48% YoY compared to Q1-FY24.
- Vitamin D3 for Human Nutrition volumes were 33% lower QoQ compared to Q4-FY24.
2 more points from Fermenta Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Fermenta Biotech Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.
Fermenta Biotech Ltd — Quarterly revenue & net profit
Fermenta Biotech Ltd Q1 FY25 results — key figures
| ₹ Cr | Q1 FY25 | Q4 FY24 | QoQ |
|---|---|---|---|
| Revenue | 78 | 97 | -19.7% |
| Operating profit (EBITDA) | 1 | 5 | -85.1% |
| Operating margin | 1.02% | 5.53% | -4.5 pp |
| Profit before tax | -6 | 1 | -751.6% |
| Net profit (PAT) | -6 | -7 | — |
| EPS (₹) | -1.98 | -2.36 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q1 FY25)
1,746 Cr, a 9% increase YoY. Key concall takeaways from Jubilant Pharmova Ltd's Q1 FY25 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q1 FY25)
Q1 FY25 revenue from operations: ₹90.75 crores, up 27.75% year-on-year (YoY) from ₹71.04 crores in Q1 FY24 (Page 8). Key concall takeaways from NGL Fine Chem…
- Shree Ganesh Rem (Q1 FY25)
Q1FY25 Revenue from Operations: ₹24.78 crore, down 8% YoY from Q1FY24's ₹26.84 crore. Key concall takeaways from Shree Ganesh Remedies Ltd's Q1 FY25 earnings…
- Themis Medicare (Q1 FY25)
122.99 Cr, up 27.26% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q1 FY25 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fermenta Biotech Ltd Q1 FY25 results?
Q1-FY25 consolidated operational revenue: INR 781 million, down 5.3% YoY (Q1-FY24: INR 824 million). Q1-FY25 Consolidated Financials: - EBITDA: INR 8 Mn (down 92.7% YoY from INR 109 Mn in Q1-FY24) - EBITDA Margin: 1.02% (down from 13.26% YoY) - Profit After Tax (PAT): INR (59) Mn (loss, compa
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.